^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Excerpt:
A proposed treatment algorithm for the management of hormone receptor (HR)-positive, HER2-negative MBC...Recommendations...Second-line treatment...The combination of a taxane or capecitabine with bevacizumab...is an option for the first line of ChT...
Secondary therapy:
capecitabine
DOI:
https://doi.org/10.1016/j.annonc.2021.09.019.
Source:
Title:
Neoadjuvant Endocrine Treatment +/- Bevacizumab in postmenopausal Patients with Operable Primary, HER2-neu negative Breast Cancer (including Lobular Cancer) (I) not suitable for Chemotherapy or (II) unlikely to respond to Chemotherapy
Excerpt:
...- Female Patients with histologically diagnosed hormone receptor positive (ER and/or PR positive ), HER2/neu negative (IHC < 2+ or FISH negative) operable breast cancer1. ...
Trial ID:
Source:
Title:
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Excerpt:
...Patients' preference of the two treatment combinations capecitabine plus bevacizumab or everolimus in combination with exemestane after failure of standard antihormonal therapy in patients with advanced (inoperable or metastatic) HER2/neu-negative hormone receptor positive breast cancer. ...
Trial ID:
Less C2 evidence
Source:
Title:
Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group
Published date:
02/17/2022
Excerpt:
Patients with human epidermal growth factor receptor 2 (HER2)-negative mBC treated with front-line BEV in combination with chemotherapy were eligible....The median PFS and the median overall survival (OS) were 13.3 (95% CI: 11.7-14.8) and 32.3 months (95% CI: 27.7-36.9), respectively. Maintenance therapy, with hormonal agents (ET) and/or BEV, was associated with longer OS versus no maintenance therapy (47.2 versus 23.6 months; p < 0.001) in patients with hormone receptor (HR)-positive disease and BEV maintenance offered longer OS versus no maintenance in patients with HR-negative disease (52.8 versus 23.3; p = 0.023).
Secondary therapy:
Chemotherapy
DOI:
10.3390/curroncol29020105
Source:
Title:
314P - Efficacy of taxane rechallenge in early metastatic relapse of HER2-negative breast cancer patients previously treated with taxane
Published date:
09/13/2021
Excerpt:
In hormone-receptor positive (HR+)/HER2-, taxane rechallenge led to similar outcomes to those obtained with other CT for both PFS/OS; while taxane + Bev led to higher PFS.
